Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications

Ralph A Defronzo

Medicine

Press/Media: Press / Media

Period	Jun 24 2018 → Jun 26 2018

Media coverage

44

Media coverage

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	Plus Company Updates (PCU)
Country	United States
Date	6/26/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	Global English (Middle East and North Africa Financial Network)
Country	Jordan
Date	6/24/18
Persons	Ralph A Defronzo

Title Real-World Study of More than 700,000 People ...
Media name/outlet ADVFN Deutschland
Country Germany
Date 6/24/18
Persons Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	Spoke.com
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	TickerTech.com
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	KSWO
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	KNDO KNDU
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	KHQ Right Now
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	NBC12 Online
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	KSLA
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	Venture Beat Profiles
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	WTOC TV
Country	Georgia
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	Kuam News 8
Country	Guam
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	KAUZ
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	14 WFIE
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	WMBF
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	Kait 8
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	KLTV 7
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	WLBT
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	News 9
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	FOX 14 TV
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	WSFA
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	Live 5 WCSC
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	WBOC TV 16
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	WFMJ 21 - TV
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	WTVM
Country	Georgia
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	KFMB-TV
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	19 Action News
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	KOTV
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	WDAM-TV
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	WTOL-TV
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	KTRE
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	KWES NewsWest 9
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	KTVN
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	KOAM TV
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	KFVS12
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	Channel 8 Eyewitness News
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	Fox 19
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	Wave 3
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	WMCTV.com
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	WECT TV-6
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	WLOX
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	Hawaii News Now
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo

Title	Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications
Media name/outlet	WIS-TV
Country	United States
Date	6/24/18
Persons	Ralph A Defronzo